SCHEMBL17844772

SCHEMBL17844772

C(=C/c1ccccc1)\COC1CCCCO1

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 1/20 0.52
ALDH1A1 P00352 1/20 0.46
DPP4 P27487 1/20 0.44
IDO1 P14902 2/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
KDM4C Q9H3R0 1/20 0.42
KDM4E B2RXH2 1/20 0.41
MGLL Q99685 1/20 0.40
SIGMAR1 Q99720 5/20 0.39
HTR2A P28223 4/20 0.39
HTR2C P28335 4/20 0.39
HTR2B P41595 4/20 0.39
DRD2 P14416 1/20 0.37
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17844735 1.00 OPRM1 (0.52) OPRM1ALDH1A1DPP4IDO1MEN1
SCHEMBL31419830 0.95 ALDH1A1 (0.50) OPRM1ALDH1A1DPP4IDO1MEN1
SCHEMBL9738265 0.86 OPRM1 (0.39) OPRM1ALDH1A1DPP4MEN1KMT2A
SCHEMBL9738262 0.86 OPRM1 (0.39) OPRM1ALDH1A1DPP4MEN1KMT2A
SCHEMBL7180157 0.84 ALDH1A1 (0.40) OPRM1ALDH1A1MEN1KMT2AKDM4C
SCHEMBL7180161 0.84 ALDH1A1 (0.40) OPRM1ALDH1A1MEN1KMT2AKDM4C
SCHEMBL8497259 0.82 MEN1 (0.50) OPRM1ALDH1A1MEN1KMT2AKDM4C
SCHEMBL25239721 0.80 MEN1 (0.46) OPRM1ALDH1A1MEN1KMT2AMGLL
SCHEMBL18143731 0.80 HPGD (0.47) KDM4ENPC1RAB9A
SCHEMBL18160519 0.80 MEN1 (0.38) OPRM1ALDH1A1MEN1KMT2AKDM4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3233859-B1 BRIDGED PYRAZOLOPYRIDINE DERIVATIVES AS ERK INHIBITORS USEFUL FOR THE TREATEMENT OF CANCER MERCK SHARP & DOHME (US) 2019-08-07 EP disclosed
US-9988397-B2 ERK inhibitors MERCK SHARP & DOHME CORP. (US) 2018-06-05 US disclosed
EP-3233859-A1 ERK INHIBITORS Merck Sharp & Dohme Corp. (US) 2017-10-25 EP disclosed
US-20170267695-A1 ERK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2017-09-21 US disclosed
WO-2016100051-A1 ERK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-06-23 WO disclosed
WO-2016095088-A1 ERK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170267695-A1 ERK INHIBITORS MAPK1, MAP3K1, MAPK4 OPRM1 4113/4885ALDH1A1 331/4885DPP4 2734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.